- Home
- RRR vs NAMS Comparison
RRR vs NAMS Comparison
Compare RRR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | NAMS |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | RRR | NAMS |
|---|---|---|
| Price | $56.23 | $35.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $61.40 | $45.80 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 15.51 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $1,995,401,000.00 | $35,243,000.00 |
| Revenue This Year | $4.13 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $17.92 | ★ N/A |
| Revenue Growth | 4.69 | ★ 4.91 |
| 52 Week Low | $35.09 | $14.06 |
| 52 Week High | $63.60 | $42.00 |
Technical Indicators
Market Signals| Indicator | RRR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 43.98 |
| Support Level | $58.02 | $34.70 |
| Resistance Level | $59.93 | $42.00 |
| Average True Range (ATR) | 1.60 | 1.99 |
| MACD | 0.01 | -0.67 |
| Stochastic Oscillator | 46.41 | 16.31 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.